Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
P2RY8-CRLF2Fusion-Positive Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Response to Novel Therapy.
Aypar U, Taylor J, Garcia JS, Momeni-Boroujeni A, Gao Q, Baik J, Londono D, Benayed R, Sigler A, Haddadin M, Penson AV, Arcila ME, Mullaney K, Sukhadia P, Quesada AE, Roshal M, Cullen N, Lako A, Rodig SJ, Goldberg AD, Zhang Y, Xiao W, Ho C. Aypar U, et al. Among authors: taylor j. JCO Precis Oncol. 2020;4:152-160. doi: 10.1200/PO.19.00294. Epub 2020 Mar 5. JCO Precis Oncol. 2020. PMID: 32395681 Free PMC article. No abstract available.
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O. Taylor J, et al. J Clin Invest. 2018 Aug 31;128(9):3819-3825. doi: 10.1172/JCI120787. Epub 2018 Aug 6. J Clin Invest. 2018. PMID: 29920189 Free PMC article.
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud N, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM. Intlekofer AM, et al. Among authors: taylor j. Nature. 2018 Jul;559(7712):125-129. doi: 10.1038/s41586-018-0251-7. Epub 2018 Jun 27. Nature. 2018. PMID: 29950729 Free PMC article.
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.
Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S, Kabel CC, Patel MA, McGovern EM, Patel A, Schulman J, Dunbar AJ, Epstein-Peterson ZD, Menghrajani KN, Getta BM, Cai SF, Geyer MB, Glass JL, Taylor J, Viny AD, Levine RL, Zhang Y, Giralt SA, Klimek V, Tallman MS, Roshal M. Xiao W, et al. Among authors: taylor j. Haematologica. 2019 Jul;104(7):1378-1387. doi: 10.3324/haematol.2018.203018. Epub 2018 Dec 6. Haematologica. 2019. PMID: 30523054 Free PMC article.
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.
Taylor J, Haddadin M, Upadhyay VA, Grussie E, Mehta-Shah N, Brunner AM, Louissaint A Jr, Lovitch SB, Dogan A, Fathi AT, Stone RM, Tallman MS, Rampal RK, Neuberg DS, Stevenson KE, Horwitz SM, Lane AA. Taylor J, et al. Blood. 2019 Aug 22;134(8):678-687. doi: 10.1182/blood.2019001144. Epub 2019 Jun 26. Blood. 2019. PMID: 31243042 Free PMC article.
Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.
Taylor J, Sendino M, Gorelick AN, Pastore A, Chang MT, Penson AV, Gavrila EI, Stewart C, Melnik EM, Herrejon Chavez F, Bitner L, Yoshimi A, Lee SC, Inoue D, Liu B, Zhang XJ, Mato AR, Dogan A, Kharas MG, Chen Y, Wang D, Soni RK, Hendrickson RC, Prieto G, Rodriguez JA, Taylor BS, Abdel-Wahab O. Taylor J, et al. Among authors: taylor bs. Cancer Discov. 2019 Oct;9(10):1452-1467. doi: 10.1158/2159-8290.CD-19-0298. Epub 2019 Jul 8. Cancer Discov. 2019. PMID: 31285298 Free PMC article.
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.
Taylor J, Mi X, Penson AV, Paffenholz SV, Alvarez K, Sigler A, Chung SS, Rampal RK, Park JH, Stein EM, Tallman MS, Sen F, Gönen M, Abdel-Wahab O, Klimek VM. Taylor J, et al. Lancet Haematol. 2020 Aug;7(8):e566-e574. doi: 10.1016/S2352-3026(20)30209-X. Lancet Haematol. 2020. PMID: 32735836 Free PMC article. Clinical Trial.
15,375 results
You have reached the last available page of results. Please see the User Guide for more information.